Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months.
IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales.
Palatin Technologies (NASDAQ: PTN) previously advanced the first FDA-approved melanocortin receptor agonist and is now developing two next-generation MC4R-selective candidates, with IND submissions targeted for the fourth quarter of 2026 and the first half of 2027.
New York, New York--(Newsfile Corp. - August 6, 2026) - Capital is flowing into rare obesity and rare endocrine diseases at an unprecedented pace. In April 2026, Neurocrine Biosciences agreed to acquire Soleno Therapeutics for roughly $2.9 billion, centered on the first approved therapy for hyperphagia associated with Prader-Willi syndrome. Three months later, Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for approximately $10.0 billion, underscoring continued strategic interest in differentiated rare endocrine assets.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/12501/308315_2744d01a0403695f_001full.jpg
At the same time, Rhythm Pharmaceuticals is demonstrating the commercial potential of MC4R-targeted therapies. The company reported $71.3 million of revenue in the second quarter of 2026 for IMCIVREE, with sequential growth driven primarily by the launch earlier this year of the first FDA-approved treatment for acquired hypothalamic obesity.
These developments have fundamentally changed the landscape for MC4R therapeutics. FDA approvals, growing commercial adoption and peer-reviewed Phase 3 data have largely validated MC4R as a therapeutic target. The next question is whether a new generation of MC4R agonists can deliver comparable efficacy with substantially improved long-term tolerability.
The competitive field has also narrowed. Acadia Pharmaceuticals discontinued its intranasal candidate for Prader-Willi hyperphagia in September 2025 after a Phase 3 miss, and Aardvark Therapeutics paused its Phase 3 HERO trial in the same disease in February 2026 over cardiac observations.
Palatin Technologies (NASDAQ: PTN) believes that opportunity remains open. After advancing bremelanotide, the first FDA-approved melanocortin receptor agonist, through FDA approval in 2019, the company is now developing two next-generation MC4R-selective candidates: a once-weekly peptide with an IND targeted for the fourth quarter of 2026 and an oral small molecule targeted for the first half of 2027. Both programs are intended for rare obesity disorders including acquired hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The objective is not simply another MC4R agonist, but a differentiated MC4R agonist designed for lifelong treatment.
IMCIVREE established MC4R agonism as an effective treatment for rare obesity disorders, but its prescribing information also highlights opportunities for improvement. The label reports generalized or focal hyperpigmentation in the majority of treated patients, recommends periodic full-body skin examinations and requires daily subcutaneous administration. For diseases that often require lifelong treatment beginning in childhood, reducing treatment burden remains an important development objective.
The biology explains why. MC4R is the receptor that signals fullness. MC1R sits on the pigment cells of the skin. A drug that activates both suppresses hunger and darkens skin at the same time. The medicinal chemistry challenge is therefore maximizing MC4R activity while minimizing MC1R activation and other off-target effects.
Recent clinical data suggest meaningful progress has been made, but the opportunity is far from exhausted. On August 4, Rhythm reported preliminary Phase 2 results for RM-718, its once-weekly MC4R-selective peptide. The study demonstrated an 11.6% mean BMI reduction at Week 16 in seven evaluable patients with acquired hypothalamic obesity and reported no generalized hyperpigmentation, although two patients experienced mild hyperpigmentation at the injection site.
At the same time, the preliminary study highlighted the remaining tolerability challenge. Among the 11 enrolled patients, 81.8% experienced injection-site reactions, 54.5% reported nausea and 27.3% experienced vomiting, while two patients (18%) discontinued treatment because of adverse events. Because the study was open label and enrolled only 11 patients, 10 of whom were White, larger studies will be needed to better characterize both efficacy and pigmentation across a larger and broader patient population.
Rhythm's oral MC4R agonist, bivamelagon, illustrates a similar challenge. Although Phase 2 results in July 2025 demonstrated encouraging efficacy, approximately half of patients receiving the 600-mg dose experienced nausea and approximately half experienced vomiting. Skin-pigmentation events were reported in the 200-mg and 400-mg cohorts, though none were reported in the 600-mg cohort, and Rhythm subsequently undertook formulation optimization before advancing the program toward pivotal trial development. It expects to initiate that trial by year-end 2026.
Taken together, these findings suggest that reducing generalized hyperpigmentation alone may not fully solve the long-term treatment burden associated with MC4R agonists. Importantly, no MC4R agonist has yet publicly reported the combination of robust efficacy, minimal generalized and local pigmentation, low gastrointestinal toxicity and good injection-site tolerability. That leaves meaningful room for continued innovation within the class.
Palatin believes that is the opportunity it is pursuing.
The company reports that its next-generation peptide and oral candidates demonstrate substantially greater MC4R selectivity and significantly reduced MC1R activity in preclinical models. Palatin believes these characteristics may reduce and potentially eliminate hyperpigmentation while also minimizing other off-target effects. Its long-acting peptide is designed for once-weekly administration, while the oral program is intended to eliminate injections entirely.
Whether those preclinical advantages translate into human studies remains unknown. Both programs remain preclinical, and clinical development, regulatory review and additional financing remain ahead.
Nevertheless, the commercial backdrop has become increasingly compelling. The MC4R pathway has now been validated by FDA approvals, peer-reviewed Phase 3 data and commercial adoption, while multibillion-dollar strategic acquisitions across rare obesity and rare endocrine diseases underscore commercial interest in the space.
The first generation of MC4R therapies proved that the biology works. The emerging second generation is demonstrating that improved receptor selectivity can reduce pigmentation. The next opportunity, and potentially the greatest commercial opportunity, may be developing an MC4R agonist that combines robust efficacy with little or no hyperpigmentation and an overall tolerability profile suitable for lifelong treatment. If Palatin can translate its preclinical pharmacology into the clinic, the company believes it has the opportunity to establish a best-in-class MC4R therapy for patients living with rare obesity disorders.
Recent News Highlights from Palatin Technologies (NASDAQ: PTN)
Palatin to Begin Trading on Nasdaq Stock Exchange
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Presents Data at ObesityWeek 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
About StreetWatch:
StreetWatch is a Wall Street Wire series on emerging and overlooked public companies. StreetWatch reports aim to provide in depth market analysis, sector context, and investor education - bringing together company developments, comparable transactions, and market dynamics into a single resource for readers looking to understand where a company sits within its broader landscape.
About Wall Street Wire and Important Disclaimers and Disclosures: Wall Street Wire is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. This article may contain forward-looking statements about the Issuer's products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer's public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Wall Street Wire receives cash compensation from Palatin Technologies, Inc. (the "Issuer") as part of a subscription to its coverage and awareness platform and services, which are provided on an ongoing subscription basis. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer. . References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist.
Contact
Wall Street Wire
coverage@wallstwire.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/308315
Source: Wall Street Wire
